

# **Scar Characteristics for Risk Stratification of Ventricular Arrhythmia in Patients with Chronic Ischemic Cardiomyopathy**

M.D. thesis in Cardiology

By

***Sherif Osama Gouda, MSc***

Under the Supervision of

***Magdy Abdel Hamid, M.D.***

Professor of Cardiology, Cairo University

***Amir Abdel Wahab, M.D.***

Lecturer of Cardiology, Cairo University

***Mohamed Ali Salem, M.D.***

Lecturer of radio-diagnosis, Cairo University

FACULTY of MEDICINE

CAIRO UNIVERSITY

2014

## ACKNOWLEDGMENTS

*First, special thanks to **Prof. Dr. Magdy Abdel Hamid**, Professor of Cardiology, Faculty of Medicine, Cairo University, for his valuable appreciated scientific supervision, constructive advices and continuous guidance.*

*Deep gratefulness to **Dr. Amir Abdel Wahab**, Lecturer of Cardiology, Faculty of Medicine, Cairo University for his priceless efforts, his valuable scientific suggestions and very important advices.*

*Special thanks to **Dr. Mohamed Ali Salem**, Lecturer of Radio-diagnosis, Faculty of Medicine, Cairo University for his valuable support and scientific suggestions.*

*Thanks to all my **colleagues** and all **workers** in the Cardiology and Radio-diagnosis Departments, for their help and support.*

*All the love for my **wife** and **son** for their endless love and encouragement.*

*All the love for my **Mother, Father and Sisters**, for their support.*

الحمد لله رب العالمين.....

**Sherif Osama Gouda**

## ABSTRACT

**Background:** Most patients with coronary artery disease (CAD) die of sudden cardiac death (SCD) or congestive heart failure. Left ventricular ejection fraction (LVEF) has its limitation as risk stratifier for SCD. Implantable cardioverter-defibrillator (ICD) is an important therapeutic modality for primary and secondary prevention of mortality in post-infarction patients with severe left ventricular (LV) dysfunction. Better risk stratification tools are needed to identify the best candidates for ICD implantation. Infarct characterization by cardiac magnetic resonance (CMR) has become an evolving potential tool for risk stratification.

**Objective:** We sought to assess scar characteristics by late gadolinium enhancement CMR (LGE-CMR) in patients with post-infarction LV dysfunction and history of spontaneous sustained monomorphic ventricular tachycardia (SMVT) and compare them with control group subjected to electrophysiological study (EPS).

**Methods:** Forty-eight patients with post-infarction LV dysfunction underwent CMR study. Twenty-four patients had history of SMVT and the other 24 were control group and underwent EPS to assess SMVT inducibility. Various scar characteristics were assessed in the spontaneous SMVT group and were compared with the inducible and non-inducible VT groups.

**Results:** All patients had LGE in CMR indicating prior myocardial infarction (MI). Out of the 24 patients in the control group, six had inducible SMVT. In univariate analysis, total scar, absolute and as percent of LV, scar core, absolute, and as percent of LV, peri-infarct zone, absolute and as percent of LV, mean infarct transmurality and number of segments with LGE were statistically significant predictors of spontaneous SMVT experience and SMVT inducibility by PES. In multivariate analysis total infarct as percent of LV was the only significant independent predictor of spontaneous SMVT experience (OR 1.33 per % change, 95% CI 1.12-1.6, p = 0.001) and SMVT inducibility (OR 1.3 per % change, 95% CI 1.1-1.6, p = 0.004). Peri-infarct zone as percent of LV became statistically non-significant predictor for spontaneous SMVT (OR 0.86 per % change, 95% CI 0.6-1.35, p = 0.5) and SMVT inducibility (OR 0.8 per % change, 95% CI 0.4-1.4, p = 0.42).

**Conclusion:** Characterization of myocardial infarct by LGE-CMR specifically total infarct size is better predictor of spontaneous SMVT experience and SMVT inducibility than LVEF. This highlights the potential importance of myocardial scarring assessment in risk stratification of patients with ischemic cardiomyopathy for selection of patients who will benefit from ICDs.

key word

SCD-SMVT-LGE,CMR- Cardiomyopathy

# Contents

<b>INTRODUCTION .....</b>	17
<b>Chapter 1: Ventricular tachycardia after myocardial infarction.....</b>	18
<b>1. Definitions and classifications of ventricular tachycardia .....</b>	18
<b>2. Mechanism of post-infarction ventricular tachycardia.....</b>	19
<b>3. Epidemiology .....</b>	22
<b>4. Clinical Presentation .....</b>	24
<b>5. Evaluation prior to catheter ablation .....</b>	25
<b>6. VT substrate imaging.....</b>	26
<b>6.1. Ventriculography.....</b>	26
<b>6.2. Echocardiography.....</b>	26
<b>6.3. Delayed contrast enhanced cardiac magnetic resonance .....</b>	27
<b>6.4. Positron emission tomography.....</b>	28
<b>6.5. Cardiac contrast enhanced computed tomography .....</b>	28
<b>7. Risk Stratification .....</b>	29
<b>7.1. Left ventricular ejection fraction .....</b>	30
<b>7.2. Other echocardiographic parameters .....</b>	30
<b>7.3. Invasive electrophysiological testing.....</b>	31
<b>7.4. Measures of cardiac repolarization .....</b>	33
<b>7.5. Measures of autonomic imbalance .....</b>	34
<b>7.6. Genetic testing .....</b>	35
<b>7.7. Cardiac magnetic resonance imaging .....</b>	35
<b>7.8. Nuclear imaging.....</b>	39
<b>7.9. Signal-averaged ECG.....</b>	41
<b>7.10. Measures of myocardial conduction disturbances .....</b>	41
<b>7.11. Risk stratification early post-infarction .....</b>	42
<b>8. Management .....</b>	43
<b>8.1. Drug therapy.....</b>	43
<b>8.2. Implantable cardioverter-defibrillator .....</b>	44
<b>8.2.1. Secondary prevention .....</b>	44
<b>8.2.2. Primary prevention .....</b>	45

<b>8.3. Catheter ablation .....</b>	46
<b>9. Localization of the site of origin of ventricular tachycardia .....</b>	47
<b>10. Electrophysiological Testing.....</b>	49
<b>10.1. Initiation of ventricular tachycardia .....</b>	49
<b>10.1.1. Protocol of programmed stimulation.....</b>	49
<b>10.1.2. Number of extrastimuli.....</b>	50
<b>10.1.3. Influence of drive cycle length.....</b>	50
<b>10.1.4. Stimulation site .....</b>	51
<b>10.1.4. Pacing current output .....</b>	52
<b>10.1.5. Facilitation by isoproterenol infusion .....</b>	52
<b>10.1.6. Reproducibility of initiation.....</b>	52
<b>10.1.7. Relationship of coupling intervals and cycle length initiating tachycardia to onset of ventricular tachycardia and initial ventricular tachycardia cycle length .....</b>	53
<b>10.1.8. Endpoints of programmed electrical stimulation .....</b>	53
<b>11. Tachycardia Features .....</b>	55
<b>12. Diagnostic maneuvers during tachycardia .....</b>	57
<b>12.1. Ventricular extrastimulation.....</b>	57
<b>12.2. Continuous resetting (entrainment).....</b>	58
<b>13. Exclusion of other arrhythmia mechanisms.....</b>	61
<b>13.1. Exclusion of triggered activity ventricular tachycardia.....</b>	61
<b>13.1.1. Inducibility with programmed electrical stimulation .....</b>	61
<b>13.1.2. Relationship of coupling intervals and cycle length initiating tachycardia to onset of ventricular tachycardia and initial ventricular tachycardia cycle length .....</b>	62
<b>13.1.3. Response to antiarrhythmic drugs .....</b>	62
<b>13.1.4. Diastolic electrical activity .....</b>	62
<b>13.2. Exclusion of bundle branch reentrant ventricular tachycardia .....</b>	63
<b>13.3. Exclusion of supraventricular tachycardia .....</b>	63
<b>13.3.1 Supraventricular tachycardia with aberrancy .....</b>	63
<b>13.3.2. Preexcited supraventricular tachycardia.....</b>	64
<b>14. Mapping.....</b>	64
<b>14.1. Activation mapping .....</b>	65
<b>14.2. Entrainment mapping .....</b>	65
<b>14.3. Pace mapping .....</b>	67

<b>14.3.1. QRS morphology during pacing versus ventricular tachycardia.....</b>	67
<b>14.3.2. Stimulus to QRS interval during pace mapping .....</b>	68
<b>14.4. Substrate mapping during baseline rhythm.....</b>	68
<b>14.5. Electroanatomical mapping .....</b>	69
<b>    14.5.1. Electroanatomical activation mapping.....</b>	69
<b>    14.5.2 Voltage mapping .....</b>	69
<b>14.6. Substrate image integration .....</b>	71
<b>14.7. Non-contact mapping.....</b>	72
<b>15. Ablation .....</b>	72
<b>    15.1. Hemodynamically stable ventricular tachycardia.....</b>	72
<b>    15.2. Multiple inducible ventricular tachycardias.....</b>	73
<b>    15.3. Unmappable ventricular tachycardia .....</b>	74
<b>16. Outcome .....</b>	76
<b>    16.1. Success and recurrence .....</b>	76
<b>    16.2. Complications .....</b>	77
<b>Chapter 2: Cardiac magnetic resonance imaging in ischemic heart disease.....</b>	79
<b>1. Cardiac MRI sequences .....</b>	79
<b>    1.1. Spin echo sequences .....</b>	79
<b>        1.1.1. Fast or turbo spin echo .....</b>	79
<b>        1.1.2. Specific spin echo sequences .....</b>	80
<b>    1.2 Spoiled gradient echo sequences .....</b>	81
<b>        1.2.1 Specific gradient echo sequences .....</b>	82
<b>    1.3. Balanced steady-state free precession.....</b>	84
<b>        1.3.1. Specific b-SSFP sequences.....</b>	86
<b>2. Contraindications to MRI .....</b>	88
<b>3. Comprehensive assessment of ischemic heart disease by CMR.....</b>	88
<b>    3.1. Functional imaging .....</b>	88
<b>    3.2. Stress functional imaging.....</b>	90
<b>    3.3. Contrast-enhanced MRI .....</b>	91
<b>        3.3.1. Imaging sequences for LGE .....</b>	93
<b>        3.3.2. Comparison of LGE to SPECT imaging.....</b>	94
<b>    3.4. Infarct size and transmural extent.....</b>	95
<b>    3.5. Infarct tissue heterogeneity.....</b>	96

<b>3.6. Microvascular obstruction (No reflow) .....</b>	97
<b>3.7. Characterization of the jeopardized myocardium .....</b>	99
<b>3.8. First-pass contrast enhanced CMR .....</b>	100
<b>3.9. Infarct-related Complications .....</b>	102
<b>3.10. Evidence of myocardial necrosis without significant underlying CAD .....</b>	102
<b>3.11. Patterns of enhancement .....</b>	103
<b>3.12. Assessment of myocardial viability before revascularization .....</b>	104
<b>3.13. Unrecognized or silent myocardial infarction .....</b>	105
<b>METHODS .....</b>	107
<b>1. Study design and patient selection.....</b>	107
<b>2. Clinical evaluation. ....</b>	107
<b>3. Transthoracic echocardiography. ....</b>	107
<b>4. Electrophysiological study. ....</b>	108
<b>5. MRI protocol.....</b>	109
<b>6. MRI analysis.....</b>	109
<b>7. Statistical analysis. ....</b>	110
<b>RESULTS .....</b>	112
<b>1. Study population.....</b>	112
<b>2. Electrophysiological study results. ....</b>	112
<b>3. MRI variables.....</b>	116
<b>4. Spontaneous and inducible VT as one group versus non-inducible group .....</b>	121
<b>5. Predictors of inducible or spontaneous VT. ....</b>	123
<b>6. Ventricular tachycardia cycle length and infarct characteristics.....</b>	127
<b>7. Scar characteristics and functional parameters by CMR .....</b>	127
<b>8. Functional parameters by TTE and comparison with CMR.....</b>	129
<b>DISCUSSION .....</b>	132
<b>1. Prior CMR-LGE studies. ....</b>	133
<b>2. Scar assessment methods.....</b>	134
<b>3. Infarct tissue heterogeneity.....</b>	135
<b>4. Spontaneous versus inducible VT groups.....</b>	137
<b>5. Ventricular tachycardia cycle length and infarct characteristics.....</b>	137
<b>6. LVEF by TTE versus CMR.....</b>	138
<b>7. Study limitations. ....</b>	138

<b>CONCLUSION AND CLINICAL IMPLICATION .....</b>	139
<b>REFERENCES.....</b>	140

## List of figures

Figure 1. Representation of a ventricular tachycardia circuit, showing a common diastolic pathway (critical isthmus), entrance and exit sites, inner and outer loops, and bystanders in three locations.	22
Figure 2. Electroanatomical (CARTO) bipolar voltage map of the left ventricle in a patient with ventricular tachycardia after anterior myocardial infarction is shown in left anterior oblique (LAO) (A) and right anterior oblique (B) projections. Voltage scale is shown at right of each panel. Red circles denote ablation sites.	71
Figure 3. LGE-CMR images for the same patient described in Figure 2. in four chamber (A) and short axis (at papillary muscle level) (B) planes showing scar involving anterior septum and anterior wall. In (B) green and red contours correspond to epicardial and endocardial borders respectively, yellow contour encircles the scar.	96
Figure 4. LGE-CMR short axis images of two of the study population, one (A) with large anterior MI with overlying thrombus (arrow) and the other (B) with inferolateral MI. In both (A) and (B) green and red contours correspond to epicardial and endocardial borders respectively, yellow contour encircles the scar.	111
Figure 5. (A) VT with RBBB pattern, right inferior axis, QRS duration of 155 ms and CL of 255 ms (B) VT with LBBB pattern, left superior axis, late precordial transition, QRS duration of 218 ms and CL of 290 ms. Both patients had LGE in CMR indicating large anterior infarctions. Pacing spikes in panel (B) are unsuccessful trials of overdrive pacing (arrow).	113
Figure 6. (A) Electroanatomical (CARTO) bipolar voltage map of the left ventricle in a patient with VT after large anterior myocardial infarction is shown in right anterior oblique projection. Red circles denote ablation sites. (B) LGE-CMR image of the same patient in four chamber plane showing the VT substrate.	114
Figure 7. Boxplots showing total infarct size absolute (A) and as percent of LV (B), scar core absolute (C) and as percent of LV (D), peri-infarct zone absolute (E) and as percent of LV (F), mean infarct transmurality (G) and number of segments with LGE (H) among the three study groups.	120
Figure 8. Receiver-operating characteristic curves for total scar (as percent of LV) for prediction of spontaneous VT (A) and VT inducibility (B)	126

Figure 9. Scatter plots showing correlation of TCL with the total infarct size absolute (A) and as percent of LV (B), scar core absolute (C) and as percent of LV (D) and peri-infarct zone absolute (E) and as percent of LV (F).....128

Figure 10. Scatter plot showing correlation between LVEF as assessed by TTE and as measured by CMR .....131

Figure 11. Bland–Altman plot for relationship of TTE and CMR assessment of LVEF .....131

## List of tables

<b>Table 1. Studies on the prognostic role of LGE-CMR.....</b>	<b>35</b>
<b>Table 2. Entrainment mapping of reentrant ventricular tachycardia .....</b>	<b>66</b>
<b>Table 3. Clinical baseline characteristics .....</b>	<b>115</b>
<b>Table 4. MRI variables among the three study groups .....</b>	<b>117</b>
<b>Table 5. MRI variables between spontaneous and inducible VT groups .....</b>	<b>118</b>
<b>Table 6. MRI variables between spontaneous and non-inducible VT groups.....</b>	<b>118</b>
<b>Table 7. MRI variables between inducible and non-inducible VT groups .....</b>	<b>119</b>
<b>Table 8. Clinical baseline characteristics in spontaneous/inducible VT versus non-inducible VT .....</b>	<b>122</b>
<b>Table 9. MRI variables in spontaneous/inducible VT versus non-inducible VT .....</b>	<b>123</b>
<b>Table 10. Univariate and multivariate analyses for spontaneous VT group with non-inducible VT group as reference.....</b>	<b>125</b>
<b>Table 11. Univariate and multivariate analyses for inducible VT group with non-inducible VT group as reference. ....</b>	<b>125</b>
<b>Table 12. Various cut-off values of total scar as percent of LV for prediction of spontaneous VT .....</b>	<b>126</b>
<b>Table 13. Various cut-off values of total scar as percent of LV for prediction of VT inducibility .....</b>	<b>126</b>
<b>Table 14. Univariate correlations between scar characteristics and functional parameters.....</b>	<b>129</b>
<b>Table 15. Functional parameters by TTE among the three study groups.....</b>	<b>130</b>
<b>Table 16. Functional parameters by TTE in spontaneous/inducible VT versus non-inducible VT .....</b>	<b>130</b>

## Abbreviations

**3D** = three-dimensional

**ACC/AHA/ESC** = American College of Cardiology/American Heart Association/European Society of Cardiology

**ACLS** = advanced cardiac life support

**ADMIRE-HF** = AdreView Myocardial Imaging for Risk Evaluation in Heart Failure

**AES** = atrial extrastimulus

**AF** = atrial fibrillation

**AFL** = atrial flutter

**AVN** = Atrioventricular nodal

**BBR** = bundle branch reentrant

**BEST-ICD** = BEta-blocker STrategy plus Implantable Cardioverter Defibrillator

**b-SSFP** = balanced steady state free precession

**CABG** = coronary artery bypass graft

**CAD** = coronary artery disease

**CARISMA** = Cardiac Arrhythmias and Risk Stratification after acute Myocardial infarction

**ce-MRA** = contrast enhanced MR angiography

**CHF** = congestive heart failure

**CL** = cycle length

**CMP** = cardiomyopathy

**CMR** = cardiac magnetic resonance

**CT** = computed tomography

**CV** = cardiovascular

**CV hosp.** = cardiovascular hospitalization

**DAD** = delayed after-depolarization

**DCM** = non-ischemic dilated cardiomyopathy

**DETERMINE** = DEfibrillators To REduce Risk by Magnetic ResoNance Imaging Evaluation

**DICOM** = Digital Imaging and Communications in Medicine

**DIR** = double inversion recovery

**DPTA** = Gd-diethylenetriamine pentaacetic acid

**ECG** = electrocardiogram

**EDV** = end-diastolic volume

**EDWT** = end-diastolic wall thickness

**EP** = electrophysiological

**EPS** = electrophysiological study

**ERP** = effective refractory period

**ESV** = end-systolic volume

**ETL** = echo train length

**FDG** = fludeoxyglucose

**FSE/TSE** = fast/turbo spin echo

**Gd** = gadolinium

**GRE** = gradient echo

**GUSTO** = Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary Arteries

**HASTE** = half acquisition single shot turbo spin echo

**HB** = His bundle

**HPS** = His-Purkinje system

**ICD** = implantable cardioverter-defibrillator

**ICE** = intracardiac echocardiography

**ICM** = ischemic cardiomyopathy

**IQR** = interquartile range

**LA** = left atrium

**LB** = left bundle

**LBBB** = left bundle branch block

**LGE-CMR** = late gadolinium enhancement cardiac magnetic resonance

**LV** = left ventricular

**LVEF** = left ventricular ejection fraction

**MADIT** = Multicenter Automatic Defibrillator Implantation Trial

**MASTER** = Microvolt T-Wave Alternans Testing for Risk Stratifications of Post MI Patients

**MBG** = myocardial blush grade

**MEA** = multielectrode array

**MI** = myocardial infarction

**MPR** = myocardial perfusion reserve

**MRCA** = MR coronary angiography

**MTWA** = microvolt T-wave alternans

**MUSTT** = Multicenter Unsustained Tachycardia Trial

**MVO** = microvascular obstruction

**NMV** = net magnetic vector

**NSR** = normal sinus rhythm

**NSVT** = non-sustained ventricular tachycardia

**NYHA** = New York Heart Association

**PCI** = percutaneous coronary intervention

**PC-MRI** = phase contrast MRI

**PES** = programmed electrical stimulation

**PET** = positron emission tomography

**PPI** = post-pacing interval

**PSIR** = phase sensitive inversion recovery

**Pt** = patient

**RBBB** = right bundle branch block